Computational Screening Strategy for Drug Repurposing Identified Niclosamide as Inhibitor of Vascular Calcification

被引:5
|
作者
Tanaka, Takeshi [1 ,2 ]
Asano, Takaharu [1 ,2 ]
Okui, Takehito [1 ,2 ]
Kuraoka, Shiori [1 ,2 ]
Singh, Sasha A. [1 ,2 ]
Aikawa, Masanori [1 ,2 ,3 ,4 ]
Aikawa, Elena [1 ,2 ,3 ,4 ]
机构
[1] Brigham & Womens Hosp, Ctr Interdisciplinary Cardiovasc Sci, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Cardiovasc Med, Ctr Excellence Vasc Biol, 75 Francis St, Boston, MA 02115 USA
[4] Sechenov First Moscow State Med Univ, Dept Human Pathol, Moscow, Russia
来源
基金
美国国家卫生研究院;
关键词
calcification; drug discovery; drug repurposing; Wnt signaling; mouse models; proteomics; CARDIOVASCULAR-DISEASE; HEPATIC STEATOSIS; CONNECTIVITY MAP; STAT3; EXPRESSION; BONE;
D O I
10.3389/fcvm.2021.826529
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vascular calcification is a cardiovascular disorder with no therapeutic options. We recently reported that o-octanoyltransferase (CROT) suppression can inhibit vascular calcification in vivo and in vitro through amelioration of mitochondrial function and fatty acid metabolism. Inhibiting calcification with a small molecule compound targeting CROT-associated mechanisms will be a promising non-invasive treatment of vascular calcification. Here we used a computational approach to search for existing drugs that can inhibit vascular calcification through the CROT pathway. For screening of the compounds that reduce CROT expression, we utilized the Connectivity Map encompassing the L1000 computational platform that contains transcription profiles of various cell lines and perturbagens including small molecules. Small molecules (n = 13) were identified and tested in human primary smooth muscle cells cultured in osteogenic media to induce calcification. Niclosamide, an FDA-improved anthelmintic drug, markedly inhibited calcification along with reduced alkaline phosphatase activity and CROT mRNA expression. To validate this compound in vivo, LDL receptor (Ldlr)-deficient mice fed a high fat diet were given oral doses of niclosamide (0 or 750 ppm admixed with diet) for 10 weeks. Niclosamide treatment decreased aortic and carotid artery calcification as determined by optical near infrared molecular imaging (OsteoSense680) and histological analysis. In addition, niclosamide improved features of fatty liver, including decreased cholesterol levels along with decreased Crot expression, while plasma total cholesterol levels did not change. Proteomic analysis of aortic samples demonstrated that niclosamide affected wingless/integrated (Wnt) signaling pathway and decreased runt-related transcription factor 2 (Runx2) expression, an essential factor for calcification. Our target discovery strategy using a genetic perturbation database with existing drugs identified niclosamide, that in turn inhibited calcification in vivo and in vitro, indicating its potential for the treatment of vascular calcification.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
    Tian-zi Wei
    Hao Wang
    Xue-qing Wu
    Yi Lu
    Sheng-hui Guan
    Feng-quan Dong
    Chen-le Dong
    Gu-li Zhu
    Yu-zhou Bao
    Jian Zhang
    Guan-yu Wang
    Hai-ying Li
    Chinese Journal of Integrative Medicine, 2020, 26 : 663 - 669
  • [22] In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy
    WEI Tian-zi
    WANG Hao
    WU Xue-qing
    LU Yi
    GUAN Sheng-hui
    DONG Feng-quan
    DONG Chen-le
    ZHU Gu-li
    BAO Yu-zhou
    ZHANG Jian
    WANG Guan-yu
    LI Hai-ying
    Chinese Journal of Integrative Medicine , 2020, (09) : 663 - 669
  • [23] COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays
    Wang, Xueqing
    Guan, Yuanfang
    MEDICINAL RESEARCH REVIEWS, 2021, 41 (01) : 5 - 28
  • [24] A network-biology led computational drug repurposing strategy to prioritize therapeutic options for COVID-19
    Khurana, Pankaj
    Varshney, Rajeev
    Gupta, Apoorv
    HELIYON, 2022, 8 (05)
  • [25] Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
    Saha, Sovan
    Halder, Anup Kumar
    Bandyopadhyay, Soumyendu Sekhar
    Chatterjee, Piyali
    Nasipuri, Mita
    Bose, Debdas
    Basu, Subhadip
    METHODS, 2022, 203 : 564 - 574
  • [26] Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening
    Du, ZH
    Lind, KE
    James, TL
    CHEMISTRY & BIOLOGY, 2002, 9 (06): : 707 - 712
  • [27] Drug repurposing through virtual screening and in vitro validation identifies tigecycline as a novel putative HCV polymerase inhibitor
    ElHefnawi, Mahmoud
    Jo, Eunji
    Tolba, Mahmoud M.
    Fares, Mohamed
    Yang, Jaewon
    Shahbaaz, Mohd
    Windisch, Marc P.
    VIROLOGY, 2022, 570 : 9 - 17
  • [28] Ligand-based drug repurposing strategy identified SARS-CoV-2 RNA G-quadruplex binders
    Moraca, Federica
    Marzano, Simona
    D'Amico, Francesco
    Lupia, Antonio
    Di Fonzo, Silvia
    Vertecchi, Eleonora
    Salvati, Erica
    Di Porzio, Anna
    Catalanotti, Bruno
    Randazzo, Antonio
    Pagano, Bruno
    Amato, Jussara
    CHEMICAL COMMUNICATIONS, 2022, 58 (85) : 11913 - 11916
  • [29] Computational approach towards repurposing of FDA approved drug molecules: strategy to combat antibiotic resistance conferred by Pseudomonas aeruginosa
    Chatterjee, Debolina
    Sivashanmugam, Karthikeyan
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024,
  • [30] Potential repurposing of four FDA approved compounds with antiplasmodial activity identified through proteome scale computational drug discovery and in vitro assay
    Bakary N’tji Diallo
    Tarryn Swart
    Heinrich C. Hoppe
    Özlem Tastan Bishop
    Kevin Lobb
    Scientific Reports, 11